DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for microcephaly — screening already-approved drugs against its 39-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMicrocephaly maps to a 39-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for microcephaly is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
mitogen-activated protein kinase 1 (MAPK1) — MAPK1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2~{s}drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8AOJ · 1.12 Å · ligand 1-[(2~{S})-2-(5-methyl-3-pyridin-4-yl-1~{H}-pyrazol-4-yl)pyrrolidin-1-yl]propan-1-one (N8L). Experimental structure, not a prediction.
What the evidence adds up to
Microcephaly is a clinical sign, not a disease entity, and can represent the extreme of normal variation. In pathological cases it is always caused by an interruption of neurobiologic processes of induction and cellular migration, or by a catastrophic insult to the central nervous system. The prime cause may be environmental or genetic, and there is strong evidence for genetic heterogeneity even among cases of 'true' or 'primary' microcephaly. A 1987 report describes a mother and son with a previously undescribed type of genetic microcephaly, featuring facial asymmetry, prominent glabella, deafness, low-set cup-shaped ears, thick protruding lower lip, micrognathia, and mental retardation. The mother became normocephalic as an adult, and her condition could not be diagnosed without childhood photographs.
A 2024 analysis of a 1906/7 Arabic medical text by Dāwūd al-Anṭākī explains microcephaly within humoral theory. Al-Anṭākī states that head shape change can be categorised into macrocephaly and microcephaly. He recommends the use of solvents for wind and fluids collected in the head, and surgical treatment (incision and evacuation) for cases in which fluids cannot be dissolved, though he provides no detailed explanation of the surgical intervention. His treatment suggestions are in line with the humoral paradigm of the period.
No modern clinical trial data, no drug intervention, and no quantitative outcomes such as survival or response rates are reported in any of these abstracts. The 1987 papers are descriptive genetic case reports; the 2024 paper is a historical textual analysis. There is no evidence of any tested pharmacological or surgical treatment for microcephaly in these sources.
What is still missing is any modern clinical trial, any drug candidate tested in patients, any quantitative measure of treatment effect, any patient stratification by genetic cause, and any funding for interventional research. Without these, the literature provides only classification and historical speculation, not a path to treatment.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Intellectual Disability Research · 1987 · 19 citations
Microcephaly: a review of genetic implications in its causation
AbstractMicrocephaly is a clinical sign rather than a nosological entity. It may even represent the extreme of normal variation. In pathological cases, it is always caused by an interruption of the neurobiologic processes of induction and cellular migration, or by a catastrophic insult to the central nervous system. The prime cause of this may be environmental or genetic. There is strong evidence for genetic heterogeneity, even among cases of 'true' or 'primary' microcephaly. Various taxonomies for the classification of microcephaly are discussed, taking into account environmental causation and various genetic mechanisms.
Syndrome of microcephaly, deafness/ malformed ears, mental retardation and peculiar facies in a mother and son
AbstractWe report a mother and son who have a microcephaly with a characteristic dysmorphic face. Prominent manifestations include facial asymmetry, prominent glabella, deafness, low-set, cup-shaped ears, thick, protruding lower lip, micrognathia, and mental retardation. We conclude that these patients have a previously undescribed type of genetic microcephaly. The mother has become normocephalic and we would not have been able to diagnose her condition without her childhood photographs. Such photographs are essential in the recognition of familial syndromes.
Turkish Neurosurgery · 2024 · 0 citations · open access
Dāwūd al-anṭākī’s account on macrocephaly and microcephaly in al-nuzhat al-mubhija
AbstractAIM: To present information regarding macrocephaly and microcephaly provided in D?w?d al-An??k??s Arabic book, al-Nuzhat al- Mubhija, which was translated into English and discussed in the context of the period?s literature. MATERIAL AND METHODS: The copy of al-Nuzhat al-Mubhija, which was published in Egypt in 1324 AH/[1906/7 AD] (2nd edition) and another copy published in Beirut, Lebanon, in 1420 AH/1999 AD, were analyzed. The section on ?the change in the shape of the head? from the copy printed in Egypt was used as the reference and the copy printed in Lebanon was compared to it. RESULTS: Al-An??k? presents that the change in head shape can be categorized into macrocephaly and microcephaly. Al-An??k? states that the head enlarges due to the separation of the cranial sutures, which occurs because of penetration of a humor between the sutures, accumulation of thick wind under the sutures, or trapping of fluids between the membranes. Al-An??k? recommends the use of solvents for the wind and fluids collected in the head, and surgical treatment (incision and evacuation) for cases in which fluids cannot be dissolved. However, he does not provide a detailed explanation about the surgical intervention. In this chapter, al- An??k? endeavors to provide an explanation of why microcephaly occurs, and organizes the treatment recommendations according to its proposed etiology. CONCLUSION: Al-An??k? briefly provides information regarding the etiology of macrocephaly and microcephaly and offers treatment suggestions for them. His treatment suggestions are in the context of and in line with the principles of humoral theory, which was the medical paradigm of the period. However, a recommendation for surgical intervention may be worth considering even in the absence of detailed information.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
